2017, a record year for global investment in Genomics with major funding rounds

, , , , , , , , , , , , , , , , , ,
Integral service around a transaction
BY : Diego GutiérrezOctober Tue, 2017
Investment in Genomics in 2017 has already surpassed last year's figure, boosted by the large rounds of funding that diagnostics startups have managed to close.

Following recent major developments in the world of genetics, such as the emergence of inexpensive sequencing technologies and gene editing tools, capital has been directed with particular interest towards genomics. 2017 has already surpassed 2016 funding levels and, if this trend continues, it is likely to double last year's figures, with a slight increase in M&A totals.

We have analysed the investment situation in the genomics sector, which consists of companies specialised in sequencing activities and analysis of genetic data, such as sequencing hardware, cancer biopsies with circulating DNA, patient test kits, etc.

Trends in genomics investment

With $1,900M invested in 65 rounds at mid-year, funding in genomics startups in 2017 has already surpassed that of 2016. Investment has mainly gone to companies specialising in cancer diagnostics and disease detection, which have been major players in this year's rounds. GRAIL raised close to $1.000M, Guardant Health has closed a round of $360M and Freenome has captured $65M.

At this pace, this year's total financing figures could be 98% higher than 2016's total of $1,700M, while M&A deal levels will be close to last year's levels. In addition, the second quarter of 2017 stands alongside the third quarter of 2015 as the record quarter for M&A deals to date.

Investment in genomics by country in recent years

The US clearly leads the world in genomics investment. Indeed, more than two-thirds of M&A deals worldwide since 2013 have been led by US companies. It is followed by the UK with around 10% of the investment and China, which, although it only raises 3% of the investment, has received significant rounds. Thus, BGI-Shenzhenwhich develops non-profit genomics studies, closed a $320M round in 2014, and NovogeneThe Beijing-based company raised $75M in 2016.

Main funding rounds in genomics in Spain

2017, a record year for global investment in Genomics with major funding rounds


Other posts that may interest you

Oryzon genomics floats on the MAB

Venture capital investments Sodena:Innoup Pharma, Davalor Salud, Iden Biotechnology


If you are looking for investors, you want to buy or selling a company, get in touch with us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?